Revolution Medicines, Inc. (RVMD) — Institutional Holders, Q2 2026 (page 8)

720 institutional investment managers reported a RVMD position on SEC Form 13F-HR for the quarter ended June 30, 2026, with a combined reported value of $40.8B. Every filer is listed below, ranked by position value, 100 per page; this page shows ranks 701 to 720. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.

RVMD 13F holders ranked 701–720 of 720

Institutional investors reporting a position in Revolution Medicines, Inc. on SEC Form 13F-HR for Q2 2026, ranked by reported value.
InstitutionValueQoQ
Creative Capital Management Investments#701 · 3 sh$562.00New
HFM Investment Advisors#702 · 3 sh$562.00-50.0%
Dunhill Financial#703 · 2 sh$405.000.0%
CoreCap Advisors#704 · 2 sh$375.00New
Abound Wealth Management#705 · 2 sh$375.00New
WEST PACES ADVISORS#706 · 2 sh$375.00New
1015 Capital Partners#707 · 2 sh$375.00New
Highland Investment Advisors#708 · 2 sh$375.00—
VALLEY NATIONAL ADVISERS#709 · 2 sh$375.00New
NBC SECURITIES#710 · 2 sh$374.00New
GHP Investment Advisors#711 · 1 sh$188.000.0%
DecisionPoint Financial#712 · 1 sh$188.00New
Trifecta Capital Advisors#713 · 1 sh$188.00New
Seneschal Advisors#714 · 1 sh$188.00New
SHP Wealth Management#715 · 1 sh$187.00New
BARTLETT & WEALTH MANAGEMENT#716 · 1 sh$187.000.0%
WPG Advisers#717 · 1 sh$187.00New
Navigoe#718 · 1 sh$0.00New
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM#719 · 238,463 sh—+44.3%
Context Capital Management#720 · 3,000,000 sh—New

Source: Form 13F-HR filings on SEC EDGAR, Q2 2026. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for Q1 2026 without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.